companyName

extensiveId

feedTypes

includeDividend

includeEstimates

includeOverview

includeOwnership

snapshotDate

CompanyName_Query

companySlug

CompanyMetaData

CompanyContent_query

company

query CompanyName_Query(
  $companyName: String!
  $extensiveId: ID
  $snapshotDate: String
  $feedTypes: [ContentType!]!
  $includeEstimates: Boolean!
  $includeOverview: Boolean!
  $includeOwnership: Boolean!
  $includeDividend: Boolean!
) {
  ...CompanyMetaData_Ux1x9
  ...CompanyContent_query_3mc3wd
}

fragment AnalystData on Analyst {
  name
  pageUrl
  jobTitle
  imgUrl
}

fragment AuthorList on Content {
  __isContent: __typename
  id
  authors {
    __typename
    id
    name
    pageUrl
  }
}

fragment ChangePercentBlock_Company on Company {
  defaultInstrument {
    isin
    symbol
    priceData {
      diff1mPercentage
      diff1yPercentage
      diff3yPercentage
      diffFromStartPercentage
    }
    id
  }
}

fragment CompactFeed_3NXCcw on Query {
  compactFeed: feedContent(companySlug: $companyName, filter: {types: $feedTypes}) {
    edges {
      node {
        __typename
        id
        ...TeaserExtraCompact_content
        createdAt
        companies {
          viewerIsFollowing
          id
        }
      }
      cursor
    }
    pageInfo {
      endCursor
      hasNextPage
    }
  }
}

fragment CompanyAnalystQuery on Company {
  analysts {
    ...AnalystData
    name
    pageUrl
    jobTitle
    imgUrl
    id
  }
}

fragment CompanyContent_query_3mc3wd on Query {
  ...CompanyHeader_query_Ux1x9
  ...CompanyOwnership_query_Ux1x9 @include(if: $includeOwnership)
  ...CompanyFinancials_query_Ux1x9 @include(if: $includeEstimates)
  ...CompanyDividend_query_Ux1x9 @include(if: $includeDividend)
  ...CompanyInvestorConsensus_query_Ux1x9
  ...CompanyPageTop_query_Ux1x9 @include(if: $includeOverview)
  ...CompanyPageBottom_query_2bVJwf @include(if: $includeOverview)
  ...CompanyDisclaimer_query_Ux1x9
  ...Extensive_query_3u4Ry5
}

fragment CompanyCoverage_Company on Company {
  analysts {
    name
    id
  }
  isPayingCustomerOf
  isFormerCustomerOf
  isCorporateCustomer
  ...CompanyAnalystQuery
  defaultInstrument {
    ...TargetAndRecommendation_Company
    id
  }
}

fragment CompanyDescription_Company on Company {
  description
  websiteUrl
  name
}

fragment CompanyDisclaimer_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    isPayingCustomerOf
    isFormerCustomerOf
    id
  }
}

fragment CompanyDividendER_query on Company {
  name
  defaultInstrument {
    estimateData {
      reportingCurrency
    }
    dividendTransactions: estimateTransactions(first: 1, includeQuarters: false) {
      actualized {
        year
        dividend
        dividendYield
        payoutPercentage
        sharePrice
      }
      estimates {
        year
        dividend
        dividendYield
        payoutPercentage
        sharePrice
      }
    }
    id
  }
}

fragment CompanyDividendNonER_query on Company {
  name
  defaultInstrument {
    nonERDividendSet: nonERCompanyNumberSet(includeQuarters: false) {
      year
      dividend
      dividendYield
      epsReported
      sharePrice
      currency
    }
    id
  }
}

fragment CompanyDividend_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    ...CompanyDividendER_query
    ...CompanyDividendNonER_query
    defaultInstrument {
      coreId
      id
    }
    id
  }
}

fragment CompanyFinancials_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    ...NonERCompanyNumbers_query
    ...CompanyNumbers_query
    defaultInstrument {
      coreId
      id
    }
    id
  }
}

fragment CompanyHeader_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    id
    companyInsref
    name
    viewerIsFollowing
    followersCount
    isCorporateCustomer
    hasPinpointData
    hasDividendHistory
    sector {
      sectorname
      industry
    }
    regions
    extensiveExists
    defaultInstrument {
      symbol
      priceData {
        tradeCurrency
        lastPrice
        diff1dPercentage
      }
      marketplace {
        name
      }
      estimates: estimateTransactions(first: 1, includeQuarters: false) {
        date
      }
      nonERCompanyNumberSet(first: 1, includeQuarters: false) {
        year
      }
      id
    }
    topOwners {
      holders {
        name
      }
    }
    transactions: insiderTransactions(filter: {types: [BUY, SELL, SUBSCRIPTION]}) {
      edges {
        node {
          date
          id
        }
      }
    }
  }
}

fragment CompanyInsiderTransactions on Company {
  name
  regions
  insiderTransactions(filter: {types: [BUY, EXERCISE_OF_SHARE_OPTION, PLEDGE, RECEPTION_OF_SHARE_PREMIUM, SELL, SUBSCRIPTION]}) {
    edges {
      node {
        insider
        position
        volume
        price
        date
        unit
        type
        relatedParty
        id
      }
    }
  }
}

fragment CompanyInvestorConsensus_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    companyInsref
    id
  }
}

fragment CompanyMetaData_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    description
    pageUrl
    defaultInstrument {
      estimateData {
        modelType
      }
      id
    }
    id
  }
}

fragment CompanyName_Slug on Company {
  slug
}

fragment CompanyNumbers_query on Company {
  name
  defaultInstrument {
    estimateData {
      modelType
      reportingCurrency
    }
    estimateTransactions(first: 1, includeQuarters: true) {
      comparisonIndexName
      actualized {
        year
        quarter
        revenue
        revenueGrowth
        ebitda
        ebitAdjusted
        ebitReported
        preTaxProfit
        netEarnings
        epsReported
        epsAdjusted
        dividend
        payoutPercentage
        roePercent
        roiPercent
        enterpriseValue
        bookValue
        marketCap
        gearingPercent
        equityRatio
        dividendYield
        totalCosts
        loanLosses
        balanceSheetTotal
        tangibleBook
        cet1
        rwa
        sharePrice
        sharesTotal
        nav
        navPerShare
        opexOfNav
        totalShareholderReturn
        comparisonIndexReturn
        netDebtTotalAsset
        quarterlySharePrice
      }
      estimates {
        year
        quarter
        revenue
        revenueGrowth
        ebitda
        ebitAdjusted
        ebitReported
        preTaxProfit
        netEarnings
        epsReported
        epsAdjusted
        dividend
        payoutPercentage
        roePercent
        roiPercent
        enterpriseValue
        bookValue
        marketCap
        gearingPercent
        equityRatio
        dividendYield
        totalCosts
        loanLosses
        balanceSheetTotal
        tangibleBook
        cet1
        rwa
        sharePrice
        sharesTotal
        nav
        navPerShare
        opexOfNav
        totalShareholderReturn
        comparisonIndexReturn
        netDebtTotalAsset
        quarterlySharePrice
      }
    }
    id
  }
}

fragment CompanyOverviewGraphs_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      companyTransactions: estimateTransactions(first: 1, includeQuarters: false) {
        actualized {
          year
          revenue
          ebitAdjusted
          epsAdjusted
          dividendYield
          navPerShare
          totalShareholderReturn
        }
        estimates {
          year
          revenue
          ebitAdjusted
          epsAdjusted
          dividendYield
          navPerShare
          totalShareholderReturn
        }
      }
      id
    }
    id
  }
}

fragment CompanyOwners on Company {
  regions
  topOwners {
    recordDate
    compareDate
    source
    holders {
      name
      capitalPercent
      votingPowerPercent
      positionChange
      totalSharesChange
      shareChange
      isNew
      isRemoved
    }
  }
}

fragment CompanyOwnership_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    ...CompanyOwners
    ...CompanyInsiderTransactions
    id
  }
}

fragment CompanyPageBottom_query_2bVJwf on Query {
  ...GeneralFeed_data_3NXCcw
  ...CompactFeed_3NXCcw
  ...UpcomingEventsQuery_Ux1x9
  ...RiskRecommendMatrix_query_Ux1x9
  ...CompanyOverviewGraphs_query_Ux1x9
  ...NonERCompanyOverviewGraphs_query_Ux1x9
  company(companySlug: $companyName) {
    companyInsref
    ...ForumUpdates_Company
    defaultInstrument {
      coreId
      id
    }
    id
  }
  allFeed: feedContent(first: 1, companySlug: $companyName, filter: {hideUpcomingVideos: true}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  main: feedContent(first: 1, companySlug: $companyName, filter: {hideUpcomingVideos: true, types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT, ANALYST_COMMENT, VIDEO, ARTICLE]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  webcasts: feedContent(first: 1, companySlug: $companyName, filter: {hideUpcomingVideos: true, types: [WEBCAST]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  thirdPartyResearch: feedContent(first: 1, companySlug: $companyName, filter: {types: [THIRD_PARTY_COMPANY_REPORT]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  releases: feedContent(first: 1, companySlug: $companyName, filter: {types: [STOCK_EXCHANGE_RELEASE, PRESS_RELEASE]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
}

fragment CompanyPageTop_query_Ux1x9 on Query {
  ...StockChart_ChartQuery_Ux1x9
  ...LatestReports_query_Ux1x9
  company(companySlug: $companyName) {
    isFund
    name
    ...CompanyCoverage_Company
    ...CompanyName_Slug
    ...CompanyDescription_Company
    ...FundNumbers_Company
    ...ChangePercentBlock_Company
    ...KeyEstimateFigures_Company
    ...InvestmentCompanyKeyFigures_Company
    defaultInstrument {
      id
      estimateData {
        modelType
      }
    }
    analysts {
      name
      id
    }
    id
  }
  extensiveReport: feedContent(first: 1, companySlug: $companyName, filter: {types: [EXTENSIVE_COMPANY_REPORT]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  analysis: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku", "Arvonluojat"]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  analysisArvonluojat: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku"]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment Extensive_query_3u4Ry5 on Query {
  company(companySlug: $companyName) {
    extensive(extensiveId: $extensiveId, snapshotDate: $snapshotDate) {
      publishedAt
      pageUrl
      content {
        id
        title
        lang
        slug
        htmlBody
        publishedAt
        createdAt
        changedAt
        isOutdated
      }
    }
    id
  }
}

fragment ForumUpdates_Company on Company {
  name
  forum {
    threadUrl
    highlightedPosts {
      url
      author
      authorImgUrl
      text
      postedAt
      likesCount
    }
  }
}

fragment FundNumbers_Company on Company {
  defaultInstrument {
    isin
    symbol
    priceData {
      lastPrice
      ath
    }
    id
  }
}

fragment GeneralFeed_data_3NXCcw on Query {
  generalFeed: feedContent(first: 20, companySlug: $companyName, filter: {types: $feedTypes}) {
    edges {
      node {
        __typename
        id
        ...Teaser_content
        ...TeaserCompact_content
      }
      cursor
    }
    pageInfo {
      endCursor
      hasNextPage
    }
  }
}

fragment InvestmentCompanyKeyFigures_Company on Company {
  marketData {
    marketCap
  }
  defaultInstrument {
    priceData {
      tradeCurrency
      dailyTurnover
    }
    estimateData {
      modelType
    }
    estimateTransactions(first: 1, includeQuarters: true) {
      actualized {
        year
        quarter
        sharesTotal
        marketCap
        nav
        navPerShare
        dividendYield
        quarterlySharePrice
      }
      estimates {
        year
        quarter
        dividendYield
      }
    }
    id
  }
}

fragment KeyEstimateFigures_Company on Company {
  marketData {
    marketCap
  }
  defaultInstrument {
    priceData {
      tradeCurrency
      dailyTurnover
      lastPrice
      marketCap
    }
    sector
    fundamentalData {
      ebit
      eps
      sales
      dividend
    }
    estimateData {
      modelType
      estimates {
        firstEstimateYear {
          year
          bookValue
          netSales
          dividendA
          epsAdjusted
          ebitAdjusted
          hybridLoan
          noOfShares
          netDebt
          mvMinorities
          mvAssociated
          roePercent
        }
      }
    }
    estimatesSharePrice: estimateTransactions(first: 1) {
      estimates {
        sharePrice
      }
    }
    id
  }
}

fragment LatestReports_query_Ux1x9 on Query {
  extensiveReport: feedContent(first: 1, companySlug: $companyName, filter: {types: [EXTENSIVE_COMPANY_REPORT]}) {
    edges {
      node {
        __typename
        createdAt
        pageUrl
        id
      }
    }
  }
  analysis: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku", "Arvonluojat"]}) {
    edges {
      node {
        __typename
        createdAt
        pageUrl
        id
      }
    }
  }
  analysisArvonluojat: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku"]}) {
    edges {
      node {
        __typename
        createdAt
        pageUrl
        id
      }
    }
  }
}

fragment NonERCompanyNumbers_query on Company {
  name
  defaultInstrument {
    nonERNumberSet: nonERCompanyNumberSet(includeQuarters: true) {
      year
      quarter
      revenue
      ebitda
      ebitReported
      epsReported
      dividend
      sharesTotal
      roe
      roi
      enterpriseValue
      marketCap
      gearingRatio
      equityRatio
      dividendYield
      sharePrice
      currency
      evSales
      evEbitda
      evEbit
      pb
      netIncome
      ptp
    }
    id
  }
}

fragment NonERCompanyOverviewGraphs_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      overviewGraphsData: nonERCompanyNumberSet(includeQuarters: false) {
        year
        revenue
        ebitReported
        epsReported
        dividend
        dividendYield
        currency
      }
      id
    }
    id
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment RiskRecommendMatrix_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      riskData: estimateTransactions(first: 1) {
        businessRisk
        valuationRisk
      }
      id
    }
    id
  }
}

fragment StockChart_ChartQuery_Ux1x9 on Query {
  company(companySlug: $companyName) {
    isFund
    defaultInstrument {
      coreId
      id
      marketOpen
      marketClose
      marketplace {
        region
      }
      priceData {
        lastPrice
      }
      returns {
        day
        week
        month
        threeMonths
        sixMonths
        year
        threeYears
        fiveYears
        tenYears
        ytd
        total
      }
    }
    id
  }
}

fragment TargetAndRecommendation_Company on Instrument {
  estimateData {
    modelType
    researchCurrency
    estimates {
      date
      recommendation
      targetPrice
    }
  }
}

fragment TeaserCompact_content on Content {
  __isContent: __typename
  __typename
  id
  type
  title
  createdAt
  isPremium
  pageUrl
  lang
  companies {
    ...CompanyTagList
    id
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
  ...AuthorList
}

fragment TeaserExtraCompact_content on Content {
  __isContent: __typename
  id
  title
  createdAt
  pageUrl
  lang
  companies {
    name
    pageUrl
    viewerIsFollowing
    id
  }
}

fragment Teaser_content on Content {
  __isContent: __typename
  __typename
  id
  type
  title
  createdAt
  pageUrl
  imgUrl
  isPremium
  lang
  companies {
    ...CompanyTagList
    id
  }
  publishers {
    imgUrl
  }
  authors {
    __typename
    id
  }
  ... on AnalystComment {
    preview
  }
  ... on Article {
    preview
  }
  ... on CompanyReport {
    preview
  }
  ... on ThirdPartyCompanyReport {
    preview
  }
  ... on QA {
    preview
  }
  ... on Video {
    preview
    liveTime
    videoDuration
  }
  ... on Webcast {
    preview
    liveTime
  }
  ...AuthorList
  ...Reactions
}

fragment UpcomingEventsQuery_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      calendarEvents(first: 10) {
        edges {
          node {
            date
            type
            period
            id
          }
        }
      }
      id
    }
    id
  }
}


name

description

pageUrl

defaultInstrument

companyInsref

viewerIsFollowing

followersCount

isCorporateCustomer

hasPinpointData

hasDividendHistory

sector

regions

extensiveExists

topOwners

insiderTransactions

isPayingCustomerOf

isFormerCustomerOf

extensive

feedContent

BICO Group

BICO Group AB has divested the Finnish property for a total of EUR 3.5m

Redeye: BICO (Q4 review): Improving outlook and trades at <1x sales

BICO, Audiocast, Q4'25

Publication of BICO Group AB: Year-end report 2025

Invitation to the presentation of BICO’s Year-end report 2025

BICO Group AB (publ) has successfully issued senior secured bonds

BICO company Biosero launches GoSimple™, a standardized automation-ready workcell with selected instruments from Sartorius and Becton, Dickinson and Company (BD)

Jesper Hagberg appointed as Chief Operations & Digital Officer for BICO Group AB

Ewa Linsäter appointed as Chief Financial Officer for BICO Group AB

Redeye: BICO (Q3 Review) - A return to organic growth and adjusted EBITDA profitability

BICO, Audiocast, Q3'25

Publication of BICO Group AB: Interim report Q3 2025

BICO provides preliminary figures for Q3 2025 and announces impairment

Invitation to the presentation of BICO’s Interim report Q3 2025

BICO Group AB’s Nomination Committee for the 2026 Annual General Meeting

Maria Rankka appointed Board Chair of BICO Group AB

Fraser McLeod appointed as Managing Director of BICO company Biosero

BICO company Biosero to develop integrated lab automation solutions to a value of 15.2 MUSD

Redeye: Redeye Initiates Coverage of BICO Group

BICO, Audiocast, Q2'25

Publication of BICO Group AB Interim report January-June 2025

BICO Group AB (publ) has repurchased convertible bonds to a total nominal amount of SEK 98m

Invitation to the presentation of BICO’s Interim report Q2 2025

BICO has completed the divestment of MatTek and Visikol

Lars Risberg appointed as General Counsel for BICO Group AB

NASDAQ Stockholm

BICO Group operates in the biotechnology industry and focuses on the development and manufacturing of technologies for cell-based research and medical development. The company's products are aimed at researchers and pharmaceutical companies. The business is global with a main presence in Europe, North America and Asia. BICO Group was founded in 2016 and is headquartered in Gothenburg, Sweden.

Herätellään tämä ketju taas henkiin Bicon 2024 tulos on tullut ulos ja parin vuoden autiomaavalluksen jälkeen näyttää itse asiassa aika hyvältä. Tappio pienentynyt ratkaisevasti vuodesta 2023 ja Q4/2024 on ollut voitollinen kvartaali.   Lähde: Investors - BICO - The Bio Convergence Company Jos joku on vielä mukana, tästä voi kyyti vielä parantua oikein hyvin. Kyllä tämä Hesulin voittaa =)

Tässä ABG:n tuoreesta rapsasta pääkohdat. Target laskettu 35 SEK (210) ja suositus laskettu HOLD (BUY). Preliminary Q2 figures and credit provision  Preliminary Q2 sales were SEK 543m (-9% vs ABGSCe 594m) and EBITDA  was SEK -20m (-165% vs ABGSCe SEK 31m). The organic growth was 9%  (ABGSCe 31%), driven by a slowdown in emerging biopharma and biotech  related to the recent macroeconomic challenges. Management has also  reviewed historical accounts receivables, which has led to a more  conservative sales process and a credit provision of SEK -59m (SEK -43m  net of COGS), which means reported EBITDA in Q2 will be SEK -63m. The  provision relates to sales in 2021 for which customers have not been able to  pay, due to the changing market environment. The products have been  returned and will be sellable to other customers. Furthermore, management  will implement a cost reduction programme to reduce expenses by SEK  100m on an annual basis, with full effect from Q1’23. Uncertainty on historical and future financials  To us this announcement is a major concern, which is exacerbated by the abrupt  departure of the CFO three months ago. With historical financial performance  now in question, we are uncertain what the true level of demand is from  customers that can make payments. Furthermore, we believe that further credit  provisions cannot be ruled out, such as from sales recorded over the last 6m that  have not yet become overdue. The Q2 figures are another concern, with the  market slowing down while BICO’s costs continue to increase rapidly. Down to HOLD on uncertainty and balance sheet concerns  We revise our estimates and turn more cautious, assuming 15% organic  growth for ’23e-’24e. Despite us assuming only modest opex growth  (~8%/y), and a large reduction in capex (SEK 500m to SEK 200m), we do  not expect BICO to generate a positive FCF until ’25e. With current cash of  SEK 1.2bn and SEK 1.5bn in convertible debt maturing ’26e, and SEK 470m  in earn-outs to be settled in ’22-’24e, we believe there is risk of an equity  issue. Considering the material uncertainty to operations and financials, we  downgrade to HOLD (BUY) with a new TP of SEK 35 (210). Financial concerns, down to HOLD  We believe that Friday’s announcement raises several questions:  If BICO’s financial results for 2021 were based on sales to customers not able  to pay for its products, what is the true financial performance of the company? Has management taken any precautionary measures for sales that occurred  over that past six months, but where products are not yet overdue? Will there be  further credit provisions? Why have customers purchased products they cannot afford, but refrained from  using them so that they now (6-18 months later) remain in a re-sellable  condition? Why has this issue not been identified earlier, such as in February, when  management “initiated measures to improve the invoicing process to reduce day  until payments”? How does this relate to the sudden departure of the CFO in April? To what company (or companies) do these issues relate? Was the company  recently acquired or was it in the Group when this happened?  Concerning developments in Q2  Beyond the sales to questionable customers, we are concerned about the  developments in Q2 where the market seemingly saw a slowdown while BICO’s  cost continued to increase. Assuming that the gross margin was 73%, cash opex  increased to SEK ~415m in Q2, which corresponds to a 15% q-o-q increase from  Q1. It should also be noted that this was during a period when management guided  that it would see only modest cost increases during the year. In our view, this  development was not addressed in the press release. Assuming that capex is  similar to previous periods, we believe the underlying EBITDA indicates a negative  FCF in the range of SEK -100m to SEK -150m in the quarter. With this in mind, we  believe the annual cost savings of SEK 100m are not enough to turn around the  development.

Tätä heinäkuun alkupuolella julkaistua uutista tänne ei oltu vielä laitettukaan: Next step in Sartorius partnership finalized: several sub-sales and distribution agreements as well as R&D project agreements have been signed                   BICO              Single Press release    BICO enables and automates the life science lab of the future.         Est. reading time: 1 minute                               Eli touko-kesäkuussa ovat solmineet sopimuksia Sartoriuksen kanssa ja sen myötä kesäkuun alun jälkeen osakekurssi onkin noussut jo +30 %.

Riskillä lisäilin isosti kun käytiin kolmenkympin alapuolella, heinäkuun kurssilasku tuntui niin yliampuvalta. Aika hyvä raportti ja tekemisen suunta näyttää taas erittäin hyvältä. Tätä kirjoittaessa +38% reaktio rapsaan                    BICO - The Bio Convergence Company              Single Press release

Bico heräilee koomasta pyrähdyksittäin. Tätä kirjoitettaessa on kaikkien aikojen yhden päivän kurssinousu.  Eli Sartorius ostaa 10% siivun Bicosta ja ne ovat uusia osakkeita, jotka liudentavat omistusta. Paradoksaalisesti tämä osakeanti aiheutti osakkeen kasvupyrähdyksen. On ainakin minulle mysteeri, miksi tällainen raju kurssireaktio. Olisiko markkinoiden yli-innostumista? Ainakin yhtiö saa runsaasti kassavarantoa tämän annin seurauksena, joten kasvun tavoittelu voi jatkua ja ehkä aiemmin suunnitellut supistustoimet ovatkin tarpeettomia tulevana vuonna? Aika näyttää.  The Board of Directors of BICO Group AB (publ) (“BICO” or the “Company”) has exercised the authorization granted by the Annual General Meeting to issue up to 6,408,626 class B shares (“New Shares”) in full, equivalent to ten percent (10%) of outstanding shares in the company  Mahdollisesti kurssireaktio voisi selittyä sillä, että Aasian markkina avautuu aivan eri lailla kuin aiemmin. En tunne Sartoriusta yhtään, joten tämän vaikutusta on vaikea arvioida, mutta jos kurssireaktio on oikea, tällä voi olla kouriintuntuva positiivinen vaikutus tulevaan liikevaihtoon.  In conjunction with the Share Issue, BICO and Sartorius have agreed on a comprehensive technology as well as sales and marketing cooperation. As part of the partnership, both companies will enter into a research & development collaboration relating to 3D cell printing and associated technologies as well as digital solutions for cell line development workflows. Additionally, it was agreed that Sartorius will become a distributor of BICO products in the Asia-Pacific (APAC) region.                    BICO - The Bio Convergence Company              Single Press release    BICO skapar framtiden för livräddande behandlingar genom att minska världens organbrist och påskynda läkemedelsutvecklingen.         Est. reading time: 1 minute

Ja takaisin kanveesiin  BICO Group AB (publ) today announces the decision to impair goodwill in Ginolis totaling SEK 625 million, ahead of the year-end report 2022 to be published on 22 February 2023.                   BICO - The Bio Convergence Company              Single Press release    BICO skapar framtiden för livräddande behandlingar genom att minska världens organbrist och påskynda läkemedelsutvecklingen.         Est. reading time: 1 minute

Bico Group Audiocast Q3/25:                   Inderes              BICO, Audiocast, Q3'25 - Inderes    Time: 2025-11-04 10:00 Language: en Language: en Sector: Health care - Pharmaceuticals & Biotechnology Activity: Audiocast with teleconference

Erik Gatenholm

Hector Daniel Martinez Avila

BICO Group

17,09 SEK

+0,06 %